Tudor Investment Corp
MLYS icon

Tudor Investment Corp’s Mineralys Therapeutics MLYS Stock Holding History

Tudor Investment Corp’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.22M Buy
155,740
+116,694
+299% +$3.42M 0.01% 1276
2025
Q4 		$1.42M Buy
+39,046
New +$1.57M ﹤0.01% 2050

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Tudor Investment Corp's MLYS Position: Q1 2026 in Review

Tudor Investment Corp increased its Mineralys Therapeutics (MLYS) stake by 299% in Q1 2026, buying an estimated $3.42M and bringing the position to 155,740 shares worth $4.22M. The position accounts for 0.01% of the portfolio, ranked #1276.

Tudor Investment Corp first reported a position in MLYS in Q4 2025 and has held it in 2 quarters since. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Tudor Investment Corp held 155,740 shares of Mineralys Therapeutics worth $4.22M as of Q1 2026.
  • Tudor Investment Corp bought 116,694 Mineralys Therapeutics shares in Q1 2026, an estimated $3.42M.
  • Mineralys Therapeutics made up 0.01% of Tudor Investment Corp's portfolio in Q1 2026, its #1276 holding.
  • Tudor Investment Corp first reported a position in Mineralys Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.